Stabilitech (AgeTech UK) Covid-19
Oral vaccine delivery systems, Covid research. Using OraPro technology, Stabilitech’s OraPro-COVID-19 can be developed within a matter of weeks. The viral vector can be developed within days and a capsule ready for animal testing can be ready within weeks. These stages are now complete, with clinical trials due to begin, pending securing funding. Because OraPro-COVID-19 is delivered in thermally stable capsules, it can be self-administered by patients without the need for needles and healthcare professionals. The delivery mechanism eliminates the risk of potentially infected people queuing for injections, removes the need for cold-chain delivery and enables the world’s most rapid deployment of vaccines.
Technology:
AgeTech Companies
Industry:
UK AgeTech 2020
Headquarters:
United Kingdom
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership